Synfacts 2009(6): 0583-0583  
DOI: 10.1055/s-0029-1216679
Synthesis of Natural Products and Potential Drugs
© Georg Thieme Verlag Stuttgart ˙ New York

Synthesis of Taranabant

Contributor(s):Philip Kocienski
D. J. Wallace*, K. R. Campos*, C. S. Schultz*, A. Klapars, D. Zewge, B. R. Crump, B. D. Phenix, J. C. McWilliams, S. Krska, Y. Sun, C.-y. Chen, F. Spindler
Merck Research Laboratories, Rahway, USA and Solvias AG, Basel, Switzerland
New Efficient Asymmetric Synthesis of Taranabant, a CB1R Inverse Agonist for the Treatment of Obesity
Org. Process Res. Dev.  2009,  13:  84-90  
Further Information

Publication History

Publication Date:
25 May 2009 (online)


Significance

Taranabant is a potential selective inverse agonist of the cannabinoid-1 receptor which is implicated in the regulation of feeding behaviour. Hence, taranabant is being developed for the treatment of obesity. The synthesis depicted incorporates three key features: (1) a simple highly stereoselective synthesis of the vinyl tosylate (AB); (2) an efficient synthesis of a tetrasubstituted enamide by palladium-catalyzed amidation (BD); and (3) a highly efficient asymmetric hydrogenation to create two adjacent stereogenic centers in a single step (EG).

Comment

An earlier synthesis based on dynamic kinetic resolution (C.-y. Chen et al. Org. Process Res. Dev. 2007, 11, 616) required the use of sodium azide to introduce the nitrogen atom and suffered from lack of any suitable solid intermediates. In the present synthesis, the direct asymmetric hydrogenation of enamide D to taranabant was precluded because the nitrile in D coordinated preferentially to the rhodium catalyst. Therefore a two-step detour (nitrile hydrolysis, DE) and amide dehydration of G was required.